Immunoprotection of recombinant Eg.myophilin against Echinococcus granulosus infection in sheep

Abstract

Abstract. The aims of the present study were to investigate the immunoprotection of recombinant Echinococcus granulosus myophilin (rEg.myophilin) against the establishment of a challenge oral infection with E. granulosus eggs, as well as to determine the mechanisms underlying this protection. Sheep were subcutaneously immunized two times with rEg.myophilin, followed by the challenge with E. granulosus eggs orally. The animals were sacrificed 44 weeks after infection and the immunoglobulin (Ig) and cytokine levels were analyzed using ELISA. The results identified significant changes in several indexes of animal immune response subsequent to immunization with rEg.myophilin. These changes included reduced number of formed cysts, as well as elevated levels of IgG, IgA and cytokines. The present data suggest that immunization with rEg.myophilin in sheep can successfully reduce the formation of cysts caused by challenge E. granulosus infection and stimulate immune response, suggesting that rEg.myophilin a has potential value as a candidate vaccine against E. granulosus.

Treatment of protoscoleces with gamma radiation: Potential immunoprotective effect against experimental murine echinococcosis

“…Our results are consistent with previous observations which showed increased levels of IL‐4 either only after immunization with recombinant antigens 18,19 or even after infestation 14 . This elevated IL‐4 has been related to stimulating the proliferation and differentiation of mature B cell and class switching to IgE which is involved in eosinophils‐related anti‐parasite immunity 14 …”

“…Therefore, finding new potential vaccine candidates or effective drugs became urgently to prevent infection, transmission by stopping the parasite's development at a specific stage of its cycle, and recurrence risks, which can occur when cysts rupture or operative leakage occurs, resulting in the dissemination of viable protoscolices to adjacent tissues and the development of secondary echinococcosis. 9 Indeed, some vaccine candidates evaluated in mice or ruminantsb s [10][11][12][13][14][15][16][17][18][19] have proven high protective immunity such as EG95 vaccine in experimental immunization trials conducted in seven countries. 20,21 Protoscolex, one component of the larval stages is an important infectious agent that contributes to the transmission of this disease.…”

miR-216b Downregulates Intestinal IL2RB to Inhibit the Invasion of Echinococcus granulosus Eggs in the Kazakh Sheep

“…Currently, the main methods of CE treatment include drug administration and surgery, which generally involves the administration of benzimidazole such as albendazole and mebendazole (Zhu et al, 2016). The shortcomings of these methods is that they are expensive and particularly challenging in underdeveloped countries and remote areas.…”